Revolution Stalled

Kessler R. C., Chiu W. T., Demler O., Merikangas K. R., Walters E. E., Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617–627 (2005).

World Health Organization, The Global Burden of Disease. 2004 Update. (World Health Organization. Geneva 2008).

Minzenberg M. J., Carter C. S., Developing treatments for impaired cognition in schizophrenia. Trends Cogn. Sci. 16, 35–42 (2012).

Holtzheimer P. E., Mayberg H. S., Deep brain stimulation for psychiatric disorders. Annu. Rev. Neurosci. 34, 289–307 (2011).

Miller G., Is pharma running out of brainy ideas? Science 329, 502–504 (2010).

Abbott A., Novartis to shut brain research facility. Nature 480, 161–162 (2011).

Axelrod J., Whitby L. G., Hertting G., Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science 133, 383–384 (1961).

Rush A. J., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., Niederehe G., Thase M. E., Lavori P. W., Lebowitz B. D., McGrath P. J., Rosenbaum J. F., Sackeim H. A., Kupfer D. J., Luther J., Fava M., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 163, 1905–1917 (2006).

Sachs G. S., Nierenberg A. A., Calabrese J. R., Marangell L. B., Wisniewski S. R., Gyulai L., Friedman E. S., Bowden C. L., Fossey M. D., Ostacher M. J., Ketter T. A., Patel J., Hauser P., Rapport D., Martinez J. M., Allen M. H., Miklowitz D. J., Otto M. W., Dennehy E. B., Thase M. E., Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 356, 1711–1722 (2007).

Kane J., Honigfeld G., Singer J., Meltzer H., Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789–796 (1988).

Hyman S. E., Fenton W. S., Medicine. What are the right targets for psychopharmacology? Science 299, 350–351 (2003).

Heinrichs R. W., Cognitive improvement in response to antipsychotic drugs: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 631–632 (2007).

E. J. Nestler, S. E. Hyman, R. J. Malenka, Molecular Neuropharmacology: Foundation for Clinical Neuroscience (McGraw, Hill, New York, 2009).

Zarate C. A., Singh J. B., Carlson P. J., Brutsche N. E., Ameli R., Luckenbaugh D. A., Charney D. S., Manji H. K., A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006).

Lieberman J. A., Stroup T. S., McEvoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., Keefe R. S., Davis S. M., Davis C. E., Lebowitz B. D., Severe J., Hsiao J. K.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).

Nestler E. J., Hyman S. E., Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161–1169 (2010).

Seligman M. E. P., Learned helplessness. Annu. Rev. Med. 23, 407–412 (1972).

National Center for Biotechnology Information of the US National Library of Medicine, www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed. Consulted 25 August 2012.

Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry. Published online 3 April 2012.

T. S. Kuhn, The Structure of Scientific Revolutions (Univ. Chicago Press, Chicago, ed. 2, 1962).

DiMasi J. A., Feldman L., Seckler A., Wilson A., Trends in risks associated with new drug development: Success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).

D. J. Carlat, Unhinged: The Trouble with Psychiatry (Free Press, New York, 2010).

Hyman S. E., Can neuroscience be integrated into the DSM-V? Nat. Rev. Neurosci. 8, 725–732 (2007).

Konopka G., Friedrich T., Davis-Turak J., Winden K., Oldham M. C., Gao F., Chen L., Wang G. Z., Luo R., Preuss T. M., Geschwind D. H., Human-specific transcriptional networks in the brain. Neuron 75, 601–617 (2012).

Fernando A. B. P., Robbins T. W., Animal models of neuropsychiatric disorders. Annu. Rev. Clin. Psychol. 7, 39–61 (2011).

Peça J., Feliciano C., Ting J. T., Wang W., Wells M. F., Venkatraman T. N., Lascola C. D., Fu Z., Feng G., Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437–442 (2011).

Krueger D. D., Bear M. F., Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411–429 (2011).

Sullivan P. F., Daly M. J., O’Donovan M., Genetic architectures of psychiatric disorders: The emerging picture and its implications. Nat. Rev. Genet. 13, 537–551 (2012).

Yizhar O., Fenno L. E., Davidson T. J., Mogri M., Deisseroth K., Optogenetics in neural systems. Neuron 71, 9–34 (2011).

Ting J. T., Peça J., Feng G., Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu. Rev. Neurosci. 35, 49–71 (2012).

Kirov G., Pocklington A. J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., Moran J., Chambert K., Toncheva D., Georgieva L., Grozeva D., Fjodorova M., Wollerton R., Rees E., Nikolov I., van de Lagemaat L. N., Bayés A., Fernandez E., Olason P. I., Böttcher Y., Komiyama N. H., Collins M. O., Choudhary J., Stefansson K., Stefansson H., Grant S. G., Purcell S., Sklar P., O’Donovan M. C., Owen M. J., De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17, 142–153 (2012).

Brennand K. J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F. H., Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221–225 (2011).

Zhang F., Cong L., Lodato S., Kosuri S., Church G. M., Arlotta P., Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 29, 149–153 (2011).